Should personalised dosing have a role in cancer treatment?
Almost all pharmaceutical products are approved on the basis of their effect in patients representing the “average” of the population studied in registrational trials, with most drug labels allowing, at most, for empirical dose reduction in the case of toxicity. In this perspective article we explor...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-05-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full |
| _version_ | 1797833012368375808 |
|---|---|
| author | Claire C. Villette David Orrell Jim Millen Christophe Chassagnole |
| author_facet | Claire C. Villette David Orrell Jim Millen Christophe Chassagnole |
| author_sort | Claire C. Villette |
| collection | DOAJ |
| description | Almost all pharmaceutical products are approved on the basis of their effect in patients representing the “average” of the population studied in registrational trials, with most drug labels allowing, at most, for empirical dose reduction in the case of toxicity. In this perspective article we explore some of the evidence that supports the use of personalised dosing in cancer treatment and show how we have been able to build on existing models linking dose, exposure and toxicity to demonstrate how dose optimisation, including increasing the dose, has the potential to significantly improve efficacy outcomes. We also explore, through the lens of our own experience of developing a personalised dosing platform, some of the hurdles that stand in the way of implementing a personalised approach to dosing in real world settings. In particular, our experience is illustrated by the application of a dosing platform for docetaxel treatment in prostate cancer. |
| first_indexed | 2024-04-09T14:18:00Z |
| format | Article |
| id | doaj.art-f7cd6cc75d204058b037ef1c6ae0fa34 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T14:18:00Z |
| publishDate | 2023-05-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-f7cd6cc75d204058b037ef1c6ae0fa342023-05-05T06:11:16ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-05-011310.3389/fonc.2023.11544931154493Should personalised dosing have a role in cancer treatment?Claire C. VilletteDavid OrrellJim MillenChristophe ChassagnoleAlmost all pharmaceutical products are approved on the basis of their effect in patients representing the “average” of the population studied in registrational trials, with most drug labels allowing, at most, for empirical dose reduction in the case of toxicity. In this perspective article we explore some of the evidence that supports the use of personalised dosing in cancer treatment and show how we have been able to build on existing models linking dose, exposure and toxicity to demonstrate how dose optimisation, including increasing the dose, has the potential to significantly improve efficacy outcomes. We also explore, through the lens of our own experience of developing a personalised dosing platform, some of the hurdles that stand in the way of implementing a personalised approach to dosing in real world settings. In particular, our experience is illustrated by the application of a dosing platform for docetaxel treatment in prostate cancer.https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/fullcancer treatmentG-CSFDOCETAXELprostate cancerdose optimizationPK/PD model |
| spellingShingle | Claire C. Villette David Orrell Jim Millen Christophe Chassagnole Should personalised dosing have a role in cancer treatment? Frontiers in Oncology cancer treatment G-CSF DOCETAXEL prostate cancer dose optimization PK/PD model |
| title | Should personalised dosing have a role in cancer treatment? |
| title_full | Should personalised dosing have a role in cancer treatment? |
| title_fullStr | Should personalised dosing have a role in cancer treatment? |
| title_full_unstemmed | Should personalised dosing have a role in cancer treatment? |
| title_short | Should personalised dosing have a role in cancer treatment? |
| title_sort | should personalised dosing have a role in cancer treatment |
| topic | cancer treatment G-CSF DOCETAXEL prostate cancer dose optimization PK/PD model |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1154493/full |
| work_keys_str_mv | AT clairecvillette shouldpersonaliseddosinghavearoleincancertreatment AT davidorrell shouldpersonaliseddosinghavearoleincancertreatment AT jimmillen shouldpersonaliseddosinghavearoleincancertreatment AT christophechassagnole shouldpersonaliseddosinghavearoleincancertreatment |